A New Era in Asthma Management: Assessment of Asthma Control by Murphy, Kevin R. & Solis, Joel
University of Texas Rio Grande Valley 
ScholarWorks @ UTRGV 
School of Medicine Publications and 
Presentations School of Medicine 
9-2020 
A New Era in Asthma Management: Assessment of Asthma 
Control 
Kevin R. Murphy 
Joel Solis 
The University of Texas Rio Grande Valley 
Follow this and additional works at: https://scholarworks.utrgv.edu/som_pub 
 Part of the Medicine and Health Sciences Commons 
Recommended Citation 
Murphy, K. R., & Solis, J. (2020). A New Era in Asthma Management: Assessment of Asthma Control. 
Supplement to The Journal of Family Practice, 69(7), S14–S20. 
This Article is brought to you for free and open access by the School of Medicine at ScholarWorks @ UTRGV. It has 
been accepted for inclusion in School of Medicine Publications and Presentations by an authorized administrator 
of ScholarWorks @ UTRGV. For more information, please contact justin.white@utrgv.edu, 
william.flores01@utrgv.edu. 
SEPTEMBER 2020  |  Vol 69, No 7  |  Supplement to The Journal of Family Practice
A New Era in Asthma Management: 
Assessment of Asthma Control
Kevin R. Murphy, MD; Joel Solis, MD
Kevin R. Murphy, MD, Director, Clinical Research, Allergy, 
Asthma and Pediatric Pulmonology, Boys Town National Research 
Hospital, Boys Town, NE.
Joel Solis, MD, Valley Medical Arts Clinic, The University of Texas 
Rio Grande Valley, McAllen, TX.
DISCLOSURES
Dr. Murphy discloses that he serves on the advisory board and/or 
speakers’ bureau for AstraZeneca, Genentech, Glaxo Smith Kline, 
Novartis, and Sanofi Regeneron. Dr. Solis and Dr. Scott have no 
disclosures to report.
ACKNOWLEDGMENT
Editorial support was provided by Gregory Scott, PharmD, RPh, at 
the Primary Care Education Consortium (PCEC).
SPONSORSHIP
This activity is sponsored by Primary Care Education Consortium 
and the Primary Care Respiratory Group and supported by funding 
from AstraZeneca Pharmaceuticals LP.
The economic burden of asthma, including costs 
incurred by absenteeism and mortality, was estimated at 
$82 billion in 2013.5 By comparison, the total economic 
burden – including lost productivity – has been estimated 
at $330 billion for heart disease and stroke and $327 billion 
for diabetes.6 The 20-year estimated burden of direct and 
indirect costs associated with asthma is $964 billion, with 
a loss of 15.5 million quality-adjusted life-years in adoles-
cents and adults.7
A key factor contributing to the burden of disease 
associated with asthma is poor adherence to treatment by 
patients.8-10 A variety of additional factors contribute, includ-
ing limited understanding among patients about asthma and 
its treatment, as well as poor patient-clinician communica-
tion.11-13 Discordance regarding asthma control is common 
between patients and clinicians.14 Patients often overestimate 
their asthma control15 or may tolerate symptoms indicative of 
poor control based on the belief that the symptoms are part 
of living with asthma.16 Collectively, these factors contribute 
to suboptimal asthma control.
ASSESSING ASTHMA CONTROL
Asthma control means the extent to which the effects of 
asthma either can be seen in the patient or have been 
reduced or resolved by treatment. Asthma control has 2 
domains: symptom control and risk factors for future poor 
outcomes, particularly flare-ups (exacerbations). It is impor-
tant to assess the patient’s future risk for exacerbations, even 
when symptom control is good. Risk factors for exacerbations 
that are independent of symptom control include a history of 
≥1 exacerbation in the previous year, socioeconomic disad-
vantages, poor treatment adherence, incorrect inhaler tech-
nique, low lung function, smoking, and blood eosinophilia.1
Many tools are available to assess asthma control and 
are listed in the TABLE.17-26 Of those tools, the Asthma Impair-
ment and Risk Questionnaire (AIRQ) and Asthma Control 
Test (ACT) are validated for patients age ≥12 years and have 
numerically scored questions providing total scores and cut 
points for varying levels of asthma control. The ACT (FIGURE 1) 
is limited to assessing symptom control with no direct mea-
sure of future risk.19,20,23
BURDEN OF DISEASE
Asthma is recognized as a chronic, heterogenous disease 
characterized by airway inflammation and a history of respi-
ratory symptoms (eg, wheeze, shortness of breath, chest 
tightness, or cough) that vary over time and in intensity.1 
Variations are often triggered by factors such as exercise, 
allergen or irritant exposure, change in weather, or viral 
respiratory tract infections. Asthma symptoms and airflow 
limitation may resolve spontaneously or in response to treat-
ment. Symptoms may be absent for weeks or months, yet air-
way hyperresponsiveness related to chronic airway inflam-
mation usually persists.1
Asthma is a common disease in children, adolescents, 
and adults that results in substantial morbidity and utilization 
of health care resources.2 In 2018, there were an estimated 5.5 
million children and 19.2 million adults in the United States 
with asthma, of whom 45% had ≥1 asthma attack.2 In 2016, 
there were nearly 10 million office visits with asthma as a 
primary diagnosis.2 One-third (33.1%) of adults with asthma 
report their health as fair or poor.3 Anxiety, depression, and 
asthma control are independent predictors of diminished 
health-related quality of life in people with asthma.4
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in the previous year, suggesting limitations in using ACT as 
a sole measure of asthma control.22 Inclusion of the wide 
array of items in AIRQ to assess both symptom control and 
future risk identified many patients with exercise limitations 
and exacerbations that were characterized by acute treat-
ment with oral corticosteroids or emergency department/
unplanned office visits, events that are not assessed by the 
ACT or many other asthma control tools for patients age ≥12 
years.
MANAGEMENT OF PATIENTS WITH  
UNCONTROLLED ASTHMA
The most up-to-date recommendations for managing 
patients with uncontrolled asthma (discussed below) were 
released by Global Initiative for Asthma (GINA) in 2020.1 
Updated recommendations by the National Asthma Educa-
tion and Prevention Program (NAEPP) Expert Panel Report-4 
(EPR-4) have been circulated in draft form and are currently 
being finalized.
Patients found to have uncontrolled asthma should con-
tinue to receive care that meets their clinical and personal 
needs and capabilities. A key step in managing a patient with 
uncontrolled asthma is to confirm the asthma diagnosis. If 
not done as part of assessing asthma control, lung function 
should be measured. In addition, reevaluation of asthma 
control is appropriate to ensure that the treatment plan is 
consistent with recommended evidence-based therapy.
Attention should be paid to verify that all modifiable 
ASTHMA IMPAIRMENT AND RISK QUESTIONNAIRE
To address the gaps in commonly used tools for assessing 
asthma control, the Asthma Impairment and Risk Ques-
tionnaire (AIRQ) was recently developed.22 The AIRQ was 
devised using a modified Delphi process by a network of 190 
US scientific experts and primary and specialty care clini-
cians with diverse practice experiences in geographic areas 
representing a high burden of disease. The AIRQ was vali-
dated using patients (N=442) from geographically diverse US 
allergy/immunology and pulmonology clinics. The symptom 
control domain of the AIRQ was validated against the ACT, 
whereas the future risk domain was validated against the 
patient’s prior-year exacerbations as documented in their 
medical record. From the initial 15 questions that assessed 
symptom control and risk, the final questionnaire includes 
10 dichotomous (yes or no) questions, 7 focusing on symp-
tom control and 3 on future risk (FIGURE 2).49 The 10 questions 
evaluate symptoms, social and physical activities, exacerba-
tions, related health care resource utilization, perception of 
asthma control, and use of rescue medications. The AIRQ 
score ranges from 0 to 10. A score of 0 or 1 indicates asthma is 
well-controlled, whereas a score of 2 to 4 indicates asthma is 
not well-controlled. A score of 5 to 10 indicates asthma is very 
poorly controlled.
The AIRQ performed exceptionally well, including a 
superior comparison to the ACT.20,22 Importantly, as shown in 
the AIRQ validation study, 31% of patients classified as well-
controlled by ACT score (≥20) had suffered ≥1 exacerbation 
TABLE. Tools for assessing asthma control
Tool
Focus Target patient 
age (y) Administered by
No. of 
items Recall timeSymptoms Risk
Asthma APGAR17,18 ü ü 5-45 Self 6 2 wk (symptoms and risk)
Asthma Control 
Questionnaire19
ü ≥11 Self 7 1 wk
ü 6-10 HCP 7 1 wk
Asthma Control Test20 ü ≥12 Self 5 4 wk
Asthma Control and 
Communication 
Instrument21
ü ü ≥12 Self 12
Since last visit (symptoms 
and risk)
Asthma Impairment and 
Risk Questionnaire22 ü ü
≥12 Self/HCP








ü ü 6-17 HCP 8 2 wk (symptoms);  
2 mo (risk)
Pediatric Asthma Control 
and Communication 
Instrument25
ü ü ≤21 Self/parent 12
2 wk (symptoms); since last 
visit/2 mo (risk)
Test for Respiratory and 
Asthma Control in Kids26 ü ü
<5 Parent 5
4 wk (symptoms);  
12 mo (risk)
Abbreviations: HCP, health care professional.
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FIGURE 1. Asthma Control Test48
[https://www.asthma.com/additional-resources/asthma-control-test.html] 
[This Web Site has been developed as a service of GlaxoSmithKline. Like any other service, in spite of our (GSK) best efforts the information in this Web Site may become out of date 
over time. Nothing on this Web Site should be construed as the giving of advice or the making of a recommendation and it should not be relied on as the basis for any decision or 
action. It is important that you rely only on the advice of a health care professional to advise you on your specific situation. GlaxoSmithKline accepts no liability for the accuracy or 
completeness or use of, nor any liability to update, the information contained on this Web Site. These materials are provided “AS IS” WITHOUT WARRANTY OF ANY KIND, EITHER 
EXPRESSED OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, THE IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR NON-IN-
FRINGEMENT. Some jurisdictions do not allow the exclusion of implied warranties, so the above exclusion may not apply to you.]
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FIGURE 2. Asthma Impairment and Risk Questionnaire49
[http://www.airqscore.com] 
[AIRQ™ is a trademark of AstraZeneca. The AIRQ™ is reproduced with permission from AstraZeneca. AstraZeneca is the copyright owner of the AIRQ™. However, third parties will 
be allowed to use the AIRQ™ free of charge. The AIRQ™ must always be used in its entirety. Except for limited reformatting the AIRQ™ may not be modified or combined with other 
instruments without prior written approval. The ten questions of the AIRQ™ must appear verbatim, in order, and together as they are presented and not divided on separate pages. 
All copyright and trademark information must be maintained as it appears on the bottom of the AIRQ™ and on all copies. The layout of the final authorized AIRQ™ may differ slightly, 
but the item wording will not change.]
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risk factors have been identified and appropriate treatment 
instituted. This strategy is particularly important for risk 
factors that do not require or respond to a step-up in control-
ler treatment. Examples include poor inhaler technique, sub-
optimal treatment adherence, home and workplace atopic 
and irritant triggers, tobacco use or exposure, and comorbid-
ities such as gastroesophageal reflux disease, nasal polyposis, 
obesity, and sleep apnea.
Patient understanding of asthma, treatment goals, and 
treatment options should be assessed and reinforced with 
further education. A guide for patients and families is avail-
able from the National Heart, Lung, and Blood Institute 
(https://www.nhlbi.nih.gov/files/docs/public/lung/SoYou-
HaveAsthma_PRINT-reduced-filesize.pdf). Patients should 
be educated about the importance of the use of anti-inflam-
matory medications, because only 39% of adults and 40% of 
children with asthma use a long-term control medication.27 
In addition, patient education should include the impor-
tance of reducing the risk of exposure to allergens or other 
sensitizing agents.1
The patient’s familiarity with their written asthma 
action plan should be assessed routinely, as this is an indi-
cator of the patient’s ability to self-manage their asthma. 
Patients should be invited to share difficulties they may be 
having with the action plan or any other issues that may 
affect treatment adherence. If difficulties are identified, 
focus a collaborative discussion on finding a solution that 
is acceptable to the patient and that they are able and will-
ing to implement. Sample written action plans are available 
from the National Heart, Lung, and Blood Institute (https://
www.nhlbi.nih.gov/health-topics/all-publications-and-
resources/asthma-action-plan) and GINA (https://gin-
asthma.org/wp-content/uploads/2019/01/GINA-Imple-
mentation-Toolbox-2019.pdf).
Objective assessment of inhaler technique is especially 
important because proper technique has a direct impact 
on patient health outcomes and treatment tolerability.28 
Because administration errors with inhaled medications 
by patients are common, and clinicians are often unfamil-
iar with proper administration technique,29-33 the use of 
authoritative patient education resources demonstrating 
proper inhaler technique – such as those by the Centers for 
FIGURE 3. Modifying treatment in adults and adolescents with uncontrolled asthma1
Abbreviations: BDP, beclomethasone dipropionate; FEV1, forced expiratory volume in 1 second; HDM SLIT, house dust mite sublingual immunotherapy; ICS, inhaled cortico-
steroid; IgE, immunoglobulin E; IL5, interleukin-5; IL5R, interleukin-5 receptor; LABA, long-acting beta2-agonist; LTRA, leukotriene receptor antagonist; OCS, oral corticoste-
roid; SABA, short-acting beta2-agonist.
© 2020, Global Initiative for Asthma, available from ginasthma.org, published in Fontana, WI, USA.
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Disease Control and Prevention – is recommended (https://
www.cdc.gov/asthma/inhaler_video/default.htm).
PHENOTYPES AND  
BIOMARKERS
The heterogeneous nature of asthma and the many clusters of 
demographic, clinical, and/or pathophysiologic characteristics 
point to the importance of recognizing asthma phenotypes and 
endotypes in patients with uncontrolled asthma.1,34 Identifying 
the asthma phenotype is especially important for patients with 
moderate or severe uncontrolled asthma because some phe-
notype-specific treatments are available. For example, omali-
zumab is indicated for allergic asthma, whereas benralizumab, 
dupilumab, mepolizumab, and reslizumab are indicated for 
the eosinophilic phenotype.
Two peripheral biomarkers (Immunoglobulin E [IgE] 
and eosinophils) are particularly helpful in identifying 
asthma phenotype and guiding treatment. IgE is the predom-
inant biomarker for allergic asthma that is produced early in 
the allergic cascade.35 The serum IgE level correlates closely 
with the presence and severity of asthma in adults, adoles-
cents, and children.36,37
Owing to the inflammatory nature of asthma, eosino-
phils are recruited through the complex interaction of cyto-
kines and other inflammatory mediators.38,39 The blood 
eosinophil count is more closely correlated with risk of 
asthma exacerbations.40 Symptom severity is increased in 
eosinophilic asthma, although symptom severity is not iden-
tified exclusively with eosinophilia.35,41-43
KEY ASTHMA TREATMENT RECOMMENDATIONS
Global Initiative for Asthma
GINA was implemented in 1993 to develop a network of 
individuals, organizations, and public health officials for the 
dissemination of information related to the care of patients 
with asthma.44 Another key purpose of GINA was to provide 
a mechanism to incorporate the results of scientific evidence 
into asthma care, leading to the first GINA report in 1995, 
developed in collaboration with the National Heart, Lung, and 
Blood Institute. The report has been updated several times, 
and recently on a yearly basis, to reflect the totality of the 
evolving evidence. Consequently, the GINA report provides 
comprehensive recommendations for the diagnosis and treat-
ment of patients with asthma.1 Key recent changes include the 
recommendations that all adults and adolescents should be 
treated with an inhaled corticosteroid (ICS) to reduce the risk 
of severe exacerbations. In addition, treatment with only a 
short-acting beta
2
-agonist is no longer recommended.
Specific recommendations for step-up therapy are 
beyond the scope of this article, as recommendations 
depend on the patient’s current therapy and asthma con-
trol. Nonetheless, step-up therapy involves either increasing 
the dose of the current controller therapy or adding another 
controller medication. For example, a patient aged ≥12 years 
whose asthma is uncontrolled with the combination of a low-
dose ICS plus a long-acting beta
2
-agonist may benefit from 
increasing to a medium-dose ICS plus a long-acting beta
2
-
agonist (FIGURE 3).1 Discussions with a patient about step-up 
therapy should consider affordability, as asthma care in the 
United States is associated with high rates of cost-related 
underuse of medications. Although the reason is unclear, 
suboptimal adherence to asthma medications does not 
appear to be directly related to income.45 Any step-up should 
be regarded as a therapeutic trial, and the response reviewed 
after 2 to 3 months.1 In some cases, for example, during viral 
infection or seasonal allergen exposure, the duration of step-
up therapy may be only 1 to 2 weeks.
National Asthma Education and Prevention Program
The NAEPP was initiated in 1989 to address the growing 
health problem of asthma in the United States.46 From the 
beginning, the NAEPP has involved a wide variety of stake-
holder groups and organizations with the general goals to 
raise awareness among all asthma stakeholders about the 
importance of asthma, as well as to promote effective, evi-
dence-based treatment so as to reduce the disease burden. 
The first guideline report was published in 1991, with subse-
quent updates and comprehensive revisions. The last com-
prehensive revision was the Expert Panel Report-3 in 2007. 
The EPR-4, which is a limited revision that focuses on 6 top-
ics, is being finalized.47
SUMMARY
Asthma is often uncontrolled in patients of all ages and is 
frequently unrecognized, resulting in a significant burden 
of disease. Consequently, assessing asthma control at every 
opportunity is critical. A wide variety of tools to assess asthma 
control are available; however, many have clinically impor-
tant limitations to their use. The AIRQ was developed recently 
to be more widely applicable, by assessing both symptom 
control and future risk domains. In patients with uncon-
trolled asthma, step-up therapy is generally required using 
evidence-based recommendations for treatment provided in 
the GINA 2020 report and soon-to-be-released NAEPP EPR-4 
report.  ●
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